Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early Experience With Neutralizing Monoclonal Antibody Therapy For COVID-19

View ORCID ProfileMark Jarrett, Warren B. Licht, View ORCID ProfileKevin Bock, View ORCID ProfileZenobia Brown, View ORCID ProfileJamie S. Hirsch, View ORCID ProfileKevin Coppa, View ORCID ProfileRajdeep Brar, Steven Bello, View ORCID ProfileIra S. Nash
doi: https://doi.org/10.1101/2021.04.09.21255219
Mark Jarrett
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA
MD, MBA, MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Jarrett
  • For correspondence: mjarrett@northwell.edu
Warren B. Licht
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Bock
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA
MD, MHCDS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin Bock
Zenobia Brown
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zenobia Brown
Jamie S. Hirsch
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA
MD, MA, MSB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jamie S. Hirsch
Kevin Coppa
2Department of Information Services, Northwell Health, New Hyde Park, New York, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin Coppa
Rajdeep Brar
2Department of Information Services, Northwell Health, New Hyde Park, New York, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rajdeep Brar
Steven Bello
3Northwell Health, Lake Success, New York, USA
PA, MHCDS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ira S. Nash
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ira S. Nash
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance Neutralizing monoclonal antibody (MAB) therapies may benefit patients with mild to moderate COVID-19 at high risk for progressing to severe COVID-19 and/or hospitalization. Studies documenting approaches to deliver MAB infusions as well as demonstrating their efficacy are lacking.

Objective We describe our experience and patient outcomes of almost 3,000 patients who received MAB infusion therapy at Northwell Health, a large integrated health care system in New York.

Design, Setting, and Participants This is a descriptive study of adult patients who received MAB therapy between November 20, 2020, to January 31, 2021, and a retrospective cohort survival analysis comparing patients who received MAB therapy prior to admission versus those who did not. A multivariable Cox model with inverse probability weighting according to the propensity score including covariates (sociodemographic, comorbidities, and presenting vital signs) was used.

Main outcomes and measures The primary outcome was in-hospital mortality; additional evaluations included ED utilization and hospitalization within 28 days of a positive COVID-19 test for patients who received MAB therapy.

Results During the study period, 2818 adult patients received MAB infusion. Following therapy and within 28 days of COVID-19 test, 123 patients (4.4%) presented to the ED and were released and 145 patients (5.1%) were hospitalized. These 145 patients were compared with 200 controls who were eligible for but did not receive MAB therapy, and were hospitalized. In the MAB group, 16 (11%) patients met the primary outcome of in-hospital mortality, versus 21 (10.5%) in the control group. In an unadjusted Cox model, the hazard ratio (HR) for time to in-hospital mortality for the MAB group was 1.38 (95% confidence interval [95% CI] 0.696-2.719). Models adjusting for demographics (HR 1.1, 95% CI 0.53-2.23), demographics and Charlson Comorbidity Index (CCI) (HR 1.22, 95% CI 0.573-2.59), and with inverse probability weighting according to propensity scores (HR 1.19, 95% CI 0.619-2.29) did not demonstrate significance. The hospitalization rate was 4.4% for patients who received MAB therapy within 0-4 days, 5% within 5-7 days, and 6.1% within ≥8 days of symptom onset (p-value = 0.15).

Conclusions and relevance Establishing the capability to provide neutralizing MAB infusion therapy requires significant planning and coordination. While this therapy may be an important treatment option for early mild to moderate COVID-19 in high-risk patients, further investigations are needed to define the optimal timing of MAB treatment in order to reduce hospitalization and mortality.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding applies

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Northwell Health IRB

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data is available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early Experience With Neutralizing Monoclonal Antibody Therapy For COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early Experience With Neutralizing Monoclonal Antibody Therapy For COVID-19
Mark Jarrett, Warren B. Licht, Kevin Bock, Zenobia Brown, Jamie S. Hirsch, Kevin Coppa, Rajdeep Brar, Steven Bello, Ira S. Nash
medRxiv 2021.04.09.21255219; doi: https://doi.org/10.1101/2021.04.09.21255219
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Early Experience With Neutralizing Monoclonal Antibody Therapy For COVID-19
Mark Jarrett, Warren B. Licht, Kevin Bock, Zenobia Brown, Jamie S. Hirsch, Kevin Coppa, Rajdeep Brar, Steven Bello, Ira S. Nash
medRxiv 2021.04.09.21255219; doi: https://doi.org/10.1101/2021.04.09.21255219

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (580)
  • Anesthesia (141)
  • Cardiovascular Medicine (1962)
  • Dentistry and Oral Medicine (253)
  • Dermatology (187)
  • Emergency Medicine (335)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (703)
  • Epidemiology (11123)
  • Forensic Medicine (8)
  • Gastroenterology (629)
  • Genetic and Genomic Medicine (3196)
  • Geriatric Medicine (310)
  • Health Economics (567)
  • Health Informatics (2049)
  • Health Policy (864)
  • Health Systems and Quality Improvement (789)
  • Hematology (310)
  • HIV/AIDS (685)
  • Infectious Diseases (except HIV/AIDS) (12742)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (318)
  • Medical Ethics (92)
  • Nephrology (337)
  • Neurology (3004)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1561)
  • Ophthalmology (478)
  • Orthopedics (186)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (386)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2799)
  • Public and Global Health (5613)
  • Radiology and Imaging (1101)
  • Rehabilitation Medicine and Physical Therapy (637)
  • Respiratory Medicine (764)
  • Rheumatology (341)
  • Sexual and Reproductive Health (315)
  • Sports Medicine (289)
  • Surgery (348)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)